How much is Talaris Therapeutics worth in 2026?

Talaris Therapeutics has a current valuation of N/A based on their Later Stage VC (Series B) round and secondary market data.

How much funding has Talaris Therapeutics raised?

Talaris Therapeutics has raised N/A in total funding across 1 funding rounds.

Talaris Therapeutics

Biotechnology

Talaris Therapeutics valuation and funding history | Last updated: September 30, 2020 | 1 funding rounds

Current Valuation

N/A

As of September 30, 2020

Total Funding Raised

N/A

Across 1 round

Last Round

Later Stage VC (Series B)

$115.0M

Last Funding

Sep 2020

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
September 30, 2020	Later Stage VC (Series B)	$115.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

Talaris Therapeutics is currently valued at N/A as of September 30, 2020.

Track Talaris Therapeutics Valuation Updates

Get notified when Talaris Therapeutics raises new funding or valuation changes

Explore More Data

Detailed analysis for Talaris Therapeutics

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Talaris Therapeutics's valuation history, funding rounds, and growth metrics.

No credit card required

What is Talaris Therapeutics Worth in 2026?

Talaris Therapeutics is a leading private company in the Biotechnology sector. Track Talaris Therapeutics's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Talaris Therapeutics Valuation is Determined

Private company valuations like Talaris Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.